ArticleThe oncologist2025
Sex-specific differences in reproductive tract lymphomas: epidemiology, clinical features, and treatment outcomes.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Lymphomas of the Female Genital Tract: Recognizing the Rare Mimicker of Gynecologic Malignancy.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe differences in the epidemiology, clinical characteristics, and treatment strategies between primary lymphoma of the female reproductive tract (PLFGT) and primary lymphoma of the male reproductive tract (PLMGT) remain unclear. MATERIALS AND
methodsA retrospective analysis of PLFGT and PLMGT data from the surveillance, epidemiology, and end results database spanning 2000 to 2021 was conducted to compare the differences in incidence rates and clinical indicators. Bar chart analysis highlighted the distribution differences between lymphoma subgroups. Multivariate Cox regression models were used to identify prognostic factors. Kaplan-Meier analysis was performed to evaluate prognostic survival outcomes.
resultsData from 724 patients with PLFGT and 2025 with PLMGT were analyzed, with diffuse large B-cell lymphoma (DLBCL) being the most prevalent subtype. The incidence of PLFGT was higher than that of PLMGT; however, the incidence rates in both groups decreased. Among DLBCL cases, the testis was the most frequent primary site in men, whereas the ovary predominated in women with follicular lymphoma. The prognostic risk factors for PLFGT included age, pathological type, primary site, surgery, and chemotherapy, whereas those for PLMGT include age, pathological type, chemotherapy, and radiation. In the DLBCL subtype of PLFGT in the study, combined chemotherapy and radiation reportedly enhance cancer-specific survival in patients in a limited stage (Ann Arbor stage I and II). In contrast, for patients with an advanced stage (Ann Arbor stage III and IV), combined chemotherapy and surgery yielded the most favorable survival outcomes. In the DLBCL subtype of PLMGT, combined chemotherapy, radiation, and surgery demonstrated the most effective therapeutic outcomes across both the limited and advanced stages.
conclusionsClinical differences were observed between PLFGT and PLMGT. Prompt and accurate identification of risk factors and implementing integrated treatment strategies are essential for optimizing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.